Advisors Preferred LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Advisors Preferred LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, HoldingsChannel reports. The fund acquired 50,171 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 681 shares in the last quarter. nVerses Capital LLC acquired a new position in Catalyst Pharmaceuticals during the third quarter worth $50,000. Larson Financial Group LLC grew its holdings in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares in the last quarter. KBC Group NV grew its holdings in Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth $134,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CPRX has been the topic of several recent research reports. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Robert W. Baird assumed coverage on shares of Catalyst Pharmaceuticals in a report on Tuesday. They issued an “outperform” rating and a $28.00 price objective on the stock. Truist Financial upped their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, Bank of America reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $32.25.

Insider Activity

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now directly owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,500 shares of company stock worth $1,754,140. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 0.7 %

Catalyst Pharmaceuticals stock opened at $22.90 on Friday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.12 and a 52-week high of $24.64. The firm has a market cap of $2.73 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 2.25 and a beta of 0.80. The company’s 50 day moving average is $22.07 and its two-hundred day moving average is $20.87.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.